scholarly journals Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy

Oncotarget ◽  
2016 ◽  
Vol 7 (9) ◽  
pp. 10174-10181 ◽  
Author(s):  
Lourdes Martín-Martín ◽  
Julia Almeida ◽  
Helena Pomares ◽  
Eva González-Barca ◽  
Pilar Bravo ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Dendritic Cell ◽  
Plasmacytoid Dendritic Cell ◽  
Central Nervous System Involvement ◽  
Intrathecal Therapy ◽  
System Involvement ◽  
Cell Neoplasm

scholarly journals Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Nil Albiol ◽  
Silvana Novelli ◽  
Anna Mozos ◽  
Marta Pratcorona ◽  
Rodrigo Martino ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Dendritic Cell ◽  
Plasmacytoid Dendritic Cell ◽  
Central Nervous System Involvement ◽  
Intrathecal Chemotherapy ◽  
Infectious Complications ◽  
Haematopoietic Stem Cell ◽  
System Involvement ◽  
Cell Neoplasm

Abstract Background We describe a patient with blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement and the outcome of venetoclax use in this setting. Case presentation A 54-year-old Caucasian male was referred to the Haematology Unit with an enlarged inguinal lymph node which was diagnostic of a blastic plasmacytoid dendritic cell neoplasm. The staging revealed disseminated disease (skin, visceral, lymph nodes, and bone marrow). He received chemotherapy with an acute myeloid leukaemia-like regime. Afterwards, he underwent allogeneic haematopoietic stem cell transplantation, though it was not successful, showing a relapse 14 months later with hepatic and central nervous system dissemination. Intrathecal chemotherapy was administered, and venetoclax (anti-bcl2 agent) was started in an off-label indication based on most recent literature. The disease halted its course for 3 months. In the end, the patient’s disease progressed and so he succumbed due to infectious complications. Conclusions Venetoclax monotherapy seems not enough to control the disease progression under CNS involvement and other treatments should be investigated.

Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm

Blood ◽  
2021 ◽  
Author(s):  
Naveen Pemmaraju ◽  
Nathaniel R Wilson ◽  
Joseph D. Khoury ◽  
Nitin Jain ◽  
Naval G. Daver ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Dendritic Cell ◽  
Plasmacytoid Dendritic Cell ◽  
Central Nervous System Involvement ◽  
System Involvement ◽  
Cell Neoplasm

Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder

2012 ◽  
Vol 54 (3) ◽  
pp. 503-506 ◽  
Author(s):  
Krzysztof Czyzewski ◽  
Jan Styczynski ◽  
Anna Krenska ◽  
Robert Debski ◽  
Olga Zajac-Spychala ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Lymphoproliferative Disorder ◽  
Central Nervous System Involvement ◽  
Intrathecal Therapy ◽  
Post Transplant ◽  
System Involvement

Central nervous system involvement in childhood brucellosis

2001 ◽  
Vol 21 (3) ◽  
pp. 291-292 ◽  
Author(s):  
Hüseyin Çaksen ◽  
Dursun Odabaş ◽  
Şükrü Arslan ◽  
Ahmet Faik Oner
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Central Nervous System Involvement ◽  
System Involvement

Central Nervous System Involvement in the Animal Model of Myodystrophy

2013 ◽  
Vol 48 (1) ◽  
pp. 71-77 ◽  
Author(s):  
Clarissa M. Comim ◽  
Bruna P. Mendonça ◽  
Diogo Dominguini ◽  
Andreza L. Cipriano ◽  
Amanda V. Steckert ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Animal Model ◽  
Nervous System ◽  
Central Nervous System Involvement ◽  
System Involvement
Sign in / Sign up

Export Citation Format

Share Document